Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines

Journal of Immunology

Volumn 167, Issue 7, 2001, Pages 3910-3918

  Crowe J E , Jr ^a   Firestone, C Y ^a   Murphy, B R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0035478634     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.7.3910     Document Type: Article

References (58)

1. Respiratory syncytial R.M
2. Respiratory syncytial virus (RSV) F G. M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively shortly-lived
3. Heterosubtypic immunity to influenza type A virus in mice: Effector mechanisms and their longevity
4. Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without "memory T cells"?
5. Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines
6. Host responses to respiratory virus infection and immunization
7. Risk relationship to age, sex, ethnic group, and maternal antibody level
8. Parainfluenza virus type 3: Seasonality and risk of infection and reinfection in young children
9. Protection of infants from infection with influenza A virus by transplacentally acquired antibody
10. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children
11. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
12. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies
13. Monoclonal antibodies protect against respiratory syncytial virus infection in mice
14. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat
15. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats
16. Experimental respiratory syncytial virus infection of adults: Possible mechanisms of resistance to infection and illness
17. Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines
18. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection
19. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection
20. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses
21. Cold-passaged temperature sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization
22. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV
23. A syncytial virus associated with epidemic disease of the lower respiratory tract in infants and young children
24. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis
25. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus (RSV cpts-248) retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees
26. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization
27. Purification and characterization of the respiratory syncytial virus fusion protein
28. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test
29. + T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies
30. + T cells
31. 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase
32. Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV)
33. Natural history of pertussis antibody in the infant and effect on vaccine response
34. Maternal antibodies partly inhibit an active antibody response to routine tetanus toxoid immunization in infants
35. Transfer of maternal antibodies results in inhibition of specific immune responses in the offspring
36. Immunogenicity of a low-passage, high-titer modified live canine parvovirus vaccine in pups with maternally derived antibodies
37. Experimental infection of fattening pigs with pseudorabies (Aujeszky's disease) virus: Efficacy of attenuated live- and inactivated virus vaccines in pigs with or without passive immunity
38. The influence of maternal immunity on the transmission of pseudorabies virus and on the effectiveness of vaccination
39. Response of young pigs to foot-and-mouth disease oil emulsion vaccination in the presence and absence of maternally derived neutralising antibodies
40. Vaccination against feline viral rhinotracheitis in kittens with maternally derived feline viral rhinotracheitis antibodies
41. Influence of maternal antibodies on vaccine responses: Inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice
42. Persistence of maternal antibody in infants beyond 12 months: Mechanism of measles vaccine failure
43. Effect of maternal antibody on IgA antibody response in nasopharyngeal secretion in infants and children during primary respiratory syncytial virus infection
44. + T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment
45. Immunological determinants of disease caused by respiratory syncytial virus
46. DNA vaccines for influenza virus: Differential effects of maternal antibody on immune responses to hemagglutinin and nucleoprotein
47. + T cells can promote survival and recovery after challenge
48. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus
49. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3
50. Evaluation of a live, cold-passaged temperature sensitive, respiratory syncytial virus (RSV) vaccine in infancy
51. Antigen-reactive cell opsonization: A mechanism of antibody-mediated immune suppression
52. Maternal immunization and the immune response of neonates to pneumococcal polysaccharides
53. Suppression of immune response to Listeria monocytogenes: Mechanism(s) of immune complex suppression
54. The regulatory effect of antibody on the immune response
55. Recruitment and activation of PTPIC in negative regulation of antigen receptor signalling by FcγRIIBI
56. Immune complex effects on urine macrophages. I. Immune complexes suppress interferon-γ induction of Ia expression
57. Priming for local and systemic antibody memory responses to bovine respiratory syncytial virus: Effect of amount of virus, virus replication, route of administration and maternal antibodies
58. Local and systemic antibody response to bovine respiratory syncytial virus infection and reinfection in calves with and without maternal antibodies